Pancreatic Cancer Research

ResearcherVA Connecticut Healthcare SystemNo recent work listed

Xiaojia Guo

Verified by OpenAlex author ID (good confidence, 0.85), identity_conf@1As of 7 November 2026

Matched on OpenAlex author ID A5103919093. Sources: OpenAlex.

Their work

Papers
3 (first author 1, last author 0)
Trials
0
Grants
0
Labs led
0
Collaborators
9
Papers, trials and grants by year

2015: 1 paper · 2016: 1 paper · 2017: none · 2018: none · 2019: none · 2020: none · 2021: 1 paper

Papers 3

  1. Renalase is a novel tissue and serological biomarker in pancreatic ductal adenocarcinoma. Co-author DOI 10.1371/journal.pone.0250539↗
  2. Inhibition of renalase expression and signaling has antitumor activity in pancreatic cancer. Co-author DOI 10.1038/srep22996↗
  3. The novel tumor angiogenic factor, adrenomedullin-2, predicts survival in pancreatic adenocarcinoma. First author DOI 10.1016/j.jss.2014.11.002↗

Closest collaborators

The 9 strongest of 9 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Charles H. Cha · 3 shared papers, 2015–2021 · strength 0.25
  2. Fred S. Gorelick · 2 shared papers, 2016–2021 · strength 0.17
  3. Gary V. Désir · 2 shared papers, 2016–2021 · strength 0.17
  4. Lindsay L. Hollander · 2 shared papers, 2015–2016 · strength 0.13
  5. Melena D. Bellin · 1 shared paper, 2021 · strength 0.12
  6. Yasheen Gao · 1 shared paper, 2021 · strength 0.12
  7. John W. Kunstman · 1 shared paper, 2021 · strength 0.12
  8. Jill Lacy · 1 shared paper, 2021 · strength 0.12
  9. Ronald R. Salem · 1 shared paper, 2015 · strength 0.07

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.